WO2011099524A1 - 放射性金属標識抗カドヘリン抗体 - Google Patents

放射性金属標識抗カドヘリン抗体 Download PDF

Info

Publication number
WO2011099524A1
WO2011099524A1 PCT/JP2011/052759 JP2011052759W WO2011099524A1 WO 2011099524 A1 WO2011099524 A1 WO 2011099524A1 JP 2011052759 W JP2011052759 W JP 2011052759W WO 2011099524 A1 WO2011099524 A1 WO 2011099524A1
Authority
WO
WIPO (PCT)
Prior art keywords
nite
antibody
radioactive metal
cadherin
labeled anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2011/052759
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
明弘 日野
朗夫 長埜
雅彦 渡邉
正 松浦
佐藤　広一
富美子 野村
克之 見供
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm RI Pharma Co Ltd
Perseus Proteomics Inc
Original Assignee
Fujifilm RI Pharma Co Ltd
Perseus Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES11742267.5T priority Critical patent/ES2656168T3/es
Priority to BR112012020116A priority patent/BR112012020116B8/pt
Priority to AU2011215267A priority patent/AU2011215267B2/en
Priority to SG2012059457A priority patent/SG183272A1/en
Priority to EP11742267.5A priority patent/EP2535358B1/en
Priority to RU2012138459/10A priority patent/RU2577125C2/ru
Priority to US13/578,462 priority patent/US8815211B2/en
Priority to NO11742267A priority patent/NO2535358T3/no
Priority to DK11742267.5T priority patent/DK2535358T3/en
Priority to HRP20180293TT priority patent/HRP20180293T1/hr
Priority to RS20180278A priority patent/RS57008B1/sr
Priority to PL11742267T priority patent/PL2535358T3/pl
Priority to SI201131433T priority patent/SI2535358T1/en
Priority to KR1020127020785A priority patent/KR101900110B1/ko
Priority to LTEP11742267.5T priority patent/LT2535358T/lt
Priority to JP2011553868A priority patent/JP5380553B2/ja
Application filed by Fujifilm RI Pharma Co Ltd, Perseus Proteomics Inc filed Critical Fujifilm RI Pharma Co Ltd
Priority to CN201180009219.2A priority patent/CN102892787B/zh
Priority to CA2789310A priority patent/CA2789310C/en
Publication of WO2011099524A1 publication Critical patent/WO2011099524A1/ja
Anticipated expiration legal-status Critical
Priority to US14/307,589 priority patent/US20140328754A1/en
Priority to CY20181100297T priority patent/CY1120012T1/el
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Definitions

  • cadherin In addition to cell adhesion, cadherin is said to be involved in embryogenesis, morphogenesis, synapse formation, synaptic plasticity, as well as cancer invasion and metastasis. Therefore, anti-cadherin antibodies have been reported to be useful for cancer treatment (Patent Documents 1 to 3).
  • the cancer therapeutic agent comprising the radioactive metal-labeled anti-cadherin antibody of the present invention as an active ingredient has high accumulation in cancer tissue and high cancer tissue shrinking effect. It can be performed. Further, by using the cancer diagnostic agent of the present invention, the effectiveness of the cancer therapeutic agent of the present invention can be predicted and the therapeutic effect can be confirmed.
  • variable region of a human antibody is expressed as a single chain antibody (scFv) on the surface of the phage by the phage display method, and a phage that binds to the antigen can be selected.
  • scFv single chain antibody
  • the DNA sequence encoding the variable region of the human antibody that binds to the antigen can be determined. If the DNA sequence of scFv that binds to the antigen is clarified, an appropriate expression vector can be prepared from the sequence to obtain a human antibody.
  • multispecific antibodies having specificity for two or more different antigens are also included.
  • a molecule binds two antigens (ie, a bispecific antibody), but the “multispecific antibody” in the present invention is directed against more (eg, three types) antigens.
  • Multispecific antibodies can be full-length antibodies, or fragments of such antibodies (eg, F (ab ′) 2 bispecific antibodies).
  • Monoclonal antibodies can be obtained by excising spleen cells from an immunized animal and fusing them with myeloma cells to produce hybridoma cells that produce monoclonal antibodies. Using methods well known in the art such as ELISA assay, Western blot analysis, or radioimmunoassay, hybridoma cells producing an antibody that recognizes the protein of interest or a fragment thereof are selected. A hybridoma that secretes the desired antibody is cloned, cultured under appropriate conditions, and the secreted antibody is recovered and purified using methods well known in the art, such as ion exchange columns, affinity chromatography, and the like. be able to.
  • the host cell system used for monoclonal antibody expression is preferably of mammalian origin.
  • a host cell line may be selected that is most suitable for the monoclonal antibody desired to be expressed.
  • Common host cell lines include CHO-derived cell lines (Chinese hamster ovary cell line), CV1 (monkey kidney line), COS (derivative of CV1 that carries SV40T antigen), SP2 / 0 (mouse myeloma), P3x63-Ag3 .653 (mouse myeloma), and 293 (human kidney), 293T (a derivative of 293 that carries the SV40T antigen), but is not limited thereto.
  • Host cell lines can be obtained from commercial facilities, the American Tissue Culture Collection (ATCC), or from published publication agencies.
  • ATCC American Tissue Culture Collection
  • the recognition site in cadherin of the anti-cadherin antibody of the present invention is preferably the 1-655 portion of SEQ ID NO: 2.
  • the antibody is reacted with a metal chelate reagent and then reacted with the radioactive metal element to form a complex.
  • a radioactive metal element is bound to an anti-cadherin antibody via a metal chelating reagent.
  • isothiocyanobenzyl DOTA, methylisothiocyanobenzyl DTPA, and cyclohexylisothiocyanobenzyl DTPA are easy to introduce metal chelates into antibodies, labeling rate, complex stability, etc. preferable.
  • the number of chelate modifications of an antibody can be calculated by measuring the molecular weight using MALDI-TOF mass spectrometry or the like, and comparing the molecular weight of an unmodified antibody with a modified antibody (US Pat. No. 7514078, Lu et al. J Pharm Sci. 94 (4), 2005, p788-797, Tedesco et al., J Clin Onco. 23 (16S), 2005, 4765).
  • the number of chelate modifications of the antibody can also be measured by chelate titration method.
  • a method using an alkaline earth metal colorimetric reagent (Arsenazo III) is known (Bradyr et al., Nucl Med Biol. 31, 795-802, 2004, Dadachova et al., Nucl Med Biol. 26, 977-982, 1999. ).
  • An anti-cadherin antibody formed by binding a radioactive metal element has high accumulation in cancer tissues and high cancer cytotoxicity, so it is less damaging to tissues other than cancer tissues and has high safety. Useful as. Further, the anti-cancer activity of an anti-cadherin antibody formed by binding a radioactive metal element is characterized by being significantly higher than the anti-cancer activity of an anti-cadherin antibody alone. The anticancer activity is particularly remarkable when the molar ratio of antibody: chelating reagent is from 1: 0.1 to 1: 4.5.
  • the cancer therapeutic agent of the present invention may be used in combination with other anticancer agents.
  • other anticancer agents include alkylating agents, antimetabolites, microtubule inhibitors, antibiotic anticancer agents, topoisomerase inhibitors, platinum preparations, molecular target drugs, hormone agents, biologics, and the like.
  • alkylating agent include nitrogen mustard anticancer agents such as cyclophosphamide, nitrosourea anticancer agents such as ranimustine, and dacarbazine.
  • the antimetabolite include 5-FU, UFT, carmofur, capecitabine, tegafur, TS-1, gemcitabine, cytarabine and the like.
  • the cancer diagnostic agent of the present invention can be used for tumor imaging.
  • the diagnostic agent of the present invention accumulates in the tumor, and radiation is produced using a device such as a single photon tomography (SPECT), positron tomography (PET), or scintillation camera.
  • SPECT single photon tomography
  • PET positron tomography
  • the tumor can be imaged by detecting.
  • a diagnostic agent is administered before treatment, and a tumor is imaged. The higher the accumulation, the higher the effect of the therapeutic agent can be predicted. It can also be used for determination of therapeutic effect.
  • the antibody used for the diagnostic agent is preferably an antibody that recognizes an epitope that competes with the therapeutic agent, and more preferably an antibody that recognizes the same epitope as the therapeutic agent. Most desirably, it is the same antibody as the therapeutic agent.
  • the obtained culture supernatant is soluble by affinity chromatography using a HisTrap (registered trademark) HP column (GE Healthcare Bioscience) and gel filtration chromatography using a Superdex (registered trademark) 200 pg column (GE Healthcare Bioscience).
  • Type CDH3 protein was obtained.
  • mice Three days after the final immunization, spleen cells were aseptically prepared from mice, and cell fusion with mouse myeloma cells SP2 / O-Ag14 or P3-X63-Ag8.653 was carried out by the polyethylene glycol method according to a conventional method.
  • C set sense primer 5'-ATGGAGWCAGACACACTSCTGYTATGGGGT-3 ': SEQ ID NO: 27
  • D Set Sense Primer (Use a mixture of the following two types of primers) 5′-ATGAGRGCCCCTGCTCCAGWTTTYTTGIGITCTT-3 ′: SEQ ID NO: 28 5′-ATGGGCWTCAAGATGRAGTCACAKWYYCWGG-3 ′: SEQ ID NO: 29
  • E Set Sense Primer (Use a mixture of the following 3 types of primers) 5′-ATGAGTTGCYCACTCAGGTCCTGGSGTT-3 ′: SEQ ID NO: 30 5′-ATGTGGGGGAYCGKTTTYAMMCTTTCAATTG-3 ′: SEQ ID NO
  • the labeled antibody was purified with a desalting column (PD-10, GE Healthcare, 17-0435-01) using PBS.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/JP2011/052759 2010-02-10 2011-02-09 放射性金属標識抗カドヘリン抗体 Ceased WO2011099524A1 (ja)

Priority Applications (20)

Application Number Priority Date Filing Date Title
RS20180278A RS57008B1 (sr) 2010-02-10 2011-02-09 Anti-kadherin antitelo obeleženo radioaktivnim metalom
AU2011215267A AU2011215267B2 (en) 2010-02-10 2011-02-09 Radioactive metal-labeled anti-cadherin antibody
SG2012059457A SG183272A1 (en) 2010-02-10 2011-02-09 Radioactive metal-labeled anti-cadherin antibody
EP11742267.5A EP2535358B1 (en) 2010-02-10 2011-02-09 Radioactive metal-labeled anti-cadherin antibody
RU2012138459/10A RU2577125C2 (ru) 2010-02-10 2011-02-09 Меченное радиоактивным металлом антитело против кадгерина
BR112012020116A BR112012020116B8 (pt) 2010-02-10 2011-02-09 Anticorpo anti-p-caderina marcado com metal radioativo, agente terapêutico contra o câncer e agente de diagnóstico de câncer que compreendem o dito anticorpo, hibridoma, bem como usos do mesmo para produzir um agente terapêutico contra o câncer e um agente de diagnóstico de câncer
NO11742267A NO2535358T3 (enExample) 2010-02-10 2011-02-09
DK11742267.5T DK2535358T3 (en) 2010-02-10 2011-02-09 RADIOACTIVE METAL LABELED ANTI-CADHERINE ANTIBODY
HRP20180293TT HRP20180293T1 (hr) 2010-02-10 2011-02-09 Anti-kadherin antitijelo obilježeno radioaktivnim metalom
PL11742267T PL2535358T3 (pl) 2010-02-10 2011-02-09 Przeciwciało przeciwko kadherynie znakowane radioaktywnym metalem
US13/578,462 US8815211B2 (en) 2010-02-10 2011-02-09 Radioactive metal-labeled anti-cadherin antibody
ES11742267.5T ES2656168T3 (es) 2010-02-10 2011-02-09 Anticuerpo anti cadherina marcado con un metal radioactivo
KR1020127020785A KR101900110B1 (ko) 2010-02-10 2011-02-09 방사성 금속 표지 항카드헤린 항체
LTEP11742267.5T LT2535358T (lt) 2010-02-10 2011-02-09 Radioaktyvus metalu žymėtas anti-kadherino antikūnas
JP2011553868A JP5380553B2 (ja) 2010-02-10 2011-02-09 放射性金属標識抗カドヘリン抗体
SI201131433T SI2535358T1 (en) 2010-02-10 2011-02-09 Radioactive metal-labeled anti-cadherin antibody
CN201180009219.2A CN102892787B (zh) 2010-02-10 2011-02-09 放射性金属标记抗钙粘素抗体
CA2789310A CA2789310C (en) 2010-02-10 2011-02-09 Radioactive metal-labeled anti-cadherin antibody
US14/307,589 US20140328754A1 (en) 2010-02-10 2014-06-18 Radioactive metal-labeled anti-cadherin antibody
CY20181100297T CY1120012T1 (el) 2010-02-10 2018-03-12 Αντισωμα καντερινης επισημασμενο με ραδιενεργο μεταλλο

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010-028028 2010-02-10
JP2010028028 2010-02-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/578,462 A-371-Of-International US8815211B2 (en) 2010-02-10 2011-02-09 Radioactive metal-labeled anti-cadherin antibody
US14/307,589 Continuation US20140328754A1 (en) 2010-02-10 2014-06-18 Radioactive metal-labeled anti-cadherin antibody

Publications (1)

Publication Number Publication Date
WO2011099524A1 true WO2011099524A1 (ja) 2011-08-18

Family

ID=44367795

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/052759 Ceased WO2011099524A1 (ja) 2010-02-10 2011-02-09 放射性金属標識抗カドヘリン抗体

Country Status (22)

Country Link
US (2) US8815211B2 (enExample)
EP (1) EP2535358B1 (enExample)
JP (2) JP5380553B2 (enExample)
KR (1) KR101900110B1 (enExample)
CN (1) CN102892787B (enExample)
AU (1) AU2011215267B2 (enExample)
BR (1) BR112012020116B8 (enExample)
CA (1) CA2789310C (enExample)
CY (1) CY1120012T1 (enExample)
DK (1) DK2535358T3 (enExample)
ES (1) ES2656168T3 (enExample)
HR (1) HRP20180293T1 (enExample)
HU (1) HUE037817T2 (enExample)
LT (1) LT2535358T (enExample)
NO (1) NO2535358T3 (enExample)
PL (1) PL2535358T3 (enExample)
PT (1) PT2535358T (enExample)
RS (1) RS57008B1 (enExample)
RU (1) RU2577125C2 (enExample)
SG (1) SG183272A1 (enExample)
SI (1) SI2535358T1 (enExample)
WO (1) WO2011099524A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039111A1 (ja) * 2011-09-16 2013-03-21 株式会社 島津製作所 病変部位の内照射治療用ナノ粒子及び治療システム
WO2014126198A1 (ja) * 2013-02-15 2014-08-21 株式会社ペルセウスプロテオミクス 抗ｃｄｈ３ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用
JPWO2012176765A1 (ja) * 2011-06-24 2015-02-23 株式会社ペルセウスプロテオミクス 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体
WO2018034354A1 (ja) * 2016-08-19 2018-02-22 富士フイルムＲｉファーマ株式会社 緩衝剤を含む組成物
WO2025089383A1 (ja) * 2023-10-26 2025-05-01 株式会社ペルセウスプロテオミクス ２２５Ａｃ標識抗ＣＤＨ３抗体
WO2025109003A1 (en) 2023-11-21 2025-05-30 3B Pharmaceuticals Gmbh P-cadherin ligands

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2535358T3 (enExample) * 2010-02-10 2018-05-19
AU2012376421A1 (en) 2012-04-04 2014-11-13 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (p-cadherin) antibody
WO2015181882A1 (ja) * 2014-05-27 2015-12-03 株式会社島津製作所 分岐型両親媒性ブロックポリマーを用いた分子集合体及び薬剤搬送システム
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
UY36401A (es) 2014-11-14 2016-06-30 Novartis Ag Conjugados anticuerpos-fármacos
WO2017120557A1 (en) * 2016-01-09 2017-07-13 Arbele Limited Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment
EP3551745A4 (en) 2016-12-12 2020-07-15 Xcella Biosciences, Inc. SCREENING METHODS AND SYSTEMS USING MICROCAPILLARY NETWORKS
RU2657761C1 (ru) * 2017-05-29 2018-06-15 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский политехнический университет" Способ диагностики опухоли
CA3156776A1 (en) 2019-11-08 2021-05-14 xCella Biosciences, Inc. Apparatus and methods for laser-based single cell recovery from microcapillary arrays
CN121426958B (zh) * 2025-12-31 2026-03-24 北京大学人民医院 一种抗cdh3纳米抗体与应用

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171496A2 (en) 1984-08-15 1986-02-19 Research Development Corporation of Japan Process for the production of a chimera monoclonal antibody
EP0239400A2 (en) 1986-03-27 1987-09-30 Medical Research Council Recombinant antibodies and methods for their production
JPH0159878B2 (enExample) 1982-05-21 1989-12-20 Yunibaashitei Obu Karifuorunia
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1995001438A1 (en) 1993-06-30 1995-01-12 Medical Research Council Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
WO1996002576A1 (en) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
JP2005522982A (ja) 2001-05-31 2005-08-04 カイロン コーポレイション 癌治療のための標的としてのｐ−カドヘリン
JP2005532343A (ja) * 2002-05-29 2005-10-27 イミューノメディクス、インコーポレイテッド 脳およびｃｎｓ腫瘍の放射免疫治療のための方法および組成物
JP2006509744A (ja) * 2002-11-14 2006-03-23 ブラッコ　イメージング　エッセ　ピ　ア 変化したタンパク質を細胞表面に呈示する腫瘍の診断および処置のための薬剤
JP2008538909A (ja) 2005-04-26 2008-11-13 ファイザー・インク Ｐ−カドヘリン抗体
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
JP2009528257A (ja) 2006-02-28 2009-08-06 オンコセラピー・サイエンス株式会社 抗ｃｄｈ３抗体のエフェクター機能を用いて細胞を障害する方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917878A (en) * 1988-05-02 1990-04-17 Thomas Jefferson University Novel use of a radiolabelled antibody against stage specific embryonic antigen for the detection of occult abscesses in mammals
WO2000026672A1 (en) * 1998-10-30 2000-05-11 Georgetown University Diagnosis of breast cancer using antibody against cadherin-11
JP2005514409A (ja) * 2001-12-28 2005-05-19 アブジェニックス・インコーポレーテッド Ｍｕｃ１８抗原に対する抗体の使用
EP1560597A4 (en) 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED CANCER GENES, POLYPEPTIDES CODED THEREIN, AND METHOD OF USE THEREOF
JP4912153B2 (ja) * 2003-12-01 2012-04-11 イミューノメディクス、インコーポレイテッド タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法
CN1977044A (zh) 2004-03-24 2007-06-06 肿瘤疗法科学股份有限公司 治疗胰腺癌的组合物和方法
KR20080083068A (ko) * 2004-05-24 2008-09-12 더 프록터 앤드 갬블 캄파니 킬레이팅제를 함유하는 비스포스포네이트의 고형의 장용 경구 투여 형태
CA2729403A1 (en) * 2008-06-30 2010-01-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
AU2010242338B2 (en) 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
CN102781964B (zh) * 2009-12-28 2015-11-25 肿瘤疗法科学股份有限公司 抗cdh3抗体及其用途
NO2535358T3 (enExample) * 2010-02-10 2018-05-19

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0159878B2 (enExample) 1982-05-21 1989-12-20 Yunibaashitei Obu Karifuorunia
EP0171496A2 (en) 1984-08-15 1986-02-19 Research Development Corporation of Japan Process for the production of a chimera monoclonal antibody
EP0239400A2 (en) 1986-03-27 1987-09-30 Medical Research Council Recombinant antibodies and methods for their production
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1995001438A1 (en) 1993-06-30 1995-01-12 Medical Research Council Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
WO1996002576A1 (en) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
JP2005522982A (ja) 2001-05-31 2005-08-04 カイロン コーポレイション 癌治療のための標的としてのｐ−カドヘリン
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
JP2005532343A (ja) * 2002-05-29 2005-10-27 イミューノメディクス、インコーポレイテッド 脳およびｃｎｓ腫瘍の放射免疫治療のための方法および組成物
JP2006509744A (ja) * 2002-11-14 2006-03-23 ブラッコ　イメージング　エッセ　ピ　ア 変化したタンパク質を細胞表面に呈示する腫瘍の診断および処置のための薬剤
JP2008538909A (ja) 2005-04-26 2008-11-13 ファイザー・インク Ｐ−カドヘリン抗体
JP2009528257A (ja) 2006-02-28 2009-08-06 オンコセラピー・サイエンス株式会社 抗ｃｄｈ３抗体のエフェクター機能を用いて細胞を障害する方法

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Molecular Biology", JOHN WILEY AND SONS, INC.
BETTER, M.; HORWITZ, A.H., METHODS ENZYMOL., vol. 178, 1989, pages 476 - 496
BIRD, R.E.; WALKER, B.W., TRENDS BIOTECHNOL., vol. 9, 1991, pages 132 - 137
BLOECHL S. ET AL: "Fractionated Locoregional Low-Dose Radioimmunotherapy Improves Survival in a Mouse Model of Diffuse-Type Gastric Cancer Using a 213Bi-Conjugated Monoclonal Antibody", CLIN. CANCER RES., vol. 11, no. 19, 2005, pages 7070S - 7074S, XP008165230 *
BRADYR ET AL., NUCL. MED. BIOL., vol. 31, 2004, pages 795 - 802
CABILLY S. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, no. 11, 1984, pages 3273 - 7
CAMPBELL: "Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology", 1984, ELSEVIER SCIENCE PUBLISHERS
CO, M.S. ET AL., J. IMMUNOL., vol. 152, 1994, pages 2968 - 2976
DADACHOVA ET AL., NUCL. MED. BIOL., vol. 26, 1999, pages 977 - 982
G. URLAUB ET AL.: "Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity", PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220, XP008004784, DOI: doi:10.1073/pnas.77.7.4216
GOUGH: "Rapid and quantitative preparation of cytoplasmic RNA from small numbers of cells", ANALYTICAL BIOCHEMISTY, vol. 173, 1988, pages 93 - 95, XP024829900, DOI: doi:10.1016/0003-2697(88)90164-9
GREEN, J. IMMUNOL. METHODS, vol. 231, 1999, pages 11 - 23
HIDEO SAJI ET AL.: "Application of Radiometallic Compounds for Medical Diagnosis and Therapy", YAKUGAKU ZASSHI, vol. 3, 2008, pages 323 - 332, XP008165619 *
JAGGI J.S. ET AL: "Selective Alpha-Particle Mediated Depletion of Tumor Vasculature with Vascular Normalization", PLOS ONE, no. 3, 2007, pages E 267, XP008165610 *
JOURNAL OF IMMUNOLOGY, vol. 169, 2002, pages 1119 - 1125
KIM ET AL.: "Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells", GENE, vol. 199, 1997, pages 293 - 301, XP004126394, DOI: doi:10.1016/S0378-1119(97)00384-3
KOZAK, M., J.: "At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells", J. MOL. BIOL., vol. 196, 1987, pages 947 - 950, XP024010432, DOI: doi:10.1016/0022-2836(87)90418-9
LAMOYI, E., METHODS ENZYMOL., vol. 121, 1986, pages 652 - 663
LU ET AL., J. PHARM. SCI., vol. 94, no. 4, 2005, pages 788 - 797
MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554
MCDEVITT M.R. ET AL: "Design and synthesis of 225Ac radioimmunopharmaceuticals", APPLIED RADIATION AND ISOTOPES, vol. 57, 2002, pages 841 - 847, XP008065850 *
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, no. 21, 1984, pages 6851 - 5
PLUCKTHUN, A.; SKERRA, A., METHODS ENZYMOL., vol. 178, 1989, pages 497 - 515
ROUSSEAUX, J. ET AL., METHODS ENZYMOL., vol. 121, 1986, pages 663 - 669
SATO, K. ET AL., CANCER RES., vol. 53, 1993, pages 851 - 856
SCHULMAN, M. ET AL.: "A better cell line for making hybridomas secreting specific antibodies", NATURE, vol. 276, 1978, pages 269 - 270
See also references of EP2535358A4
SENEKOWITSCH-SCHMIDTKE R. ET AL: "Highly Specific Tumor Binding of a 213Bi-labeled Monoclonal Antibody against Mutant E-Cadherin Suggests Its Usefulness for Locoregional alpha- Radioimmunotherapy of Diffuse-Type Gastric Cancer", CANCER RESEARCH, vol. 61, 2001, pages 2804 - 2808, XP001179836 *
ST. GROTH ET AL., J. IMMUNOL. METHODS, vol. 35, 1980, pages 1 - 21
TEDESCO ET AL., J. CLIN. ONCO., vol. 23, no. 16S, 2005, pages 4765
URLAND, G. ET AL.: "Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions", SOMAT. CELL. MOL. GENET., vol. 12, 1986, pages 5555 - 556
WATANABE T. ET AL: "Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (90Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma", CANCER SCI., vol. 96, no. 12, 2005, pages 903 - 910, XP008165606 *
WELLS, EEK, CHEM. BIOL., vol. 7, no. 8, August 2000 (2000-08-01), pages R185 - 6

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2012176765A1 (ja) * 2011-06-24 2015-02-23 株式会社ペルセウスプロテオミクス 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体
WO2013039111A1 (ja) * 2011-09-16 2013-03-21 株式会社 島津製作所 病変部位の内照射治療用ナノ粒子及び治療システム
JPWO2013039111A1 (ja) * 2011-09-16 2015-03-26 株式会社島津製作所 病変部位の内照射治療用ナノ粒子及び治療システム
WO2014126198A1 (ja) * 2013-02-15 2014-08-21 株式会社ペルセウスプロテオミクス 抗ｃｄｈ３ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用
JPWO2014126198A1 (ja) * 2013-02-15 2017-02-02 株式会社ペルセウスプロテオミクス 抗ｃｄｈ３ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用
US9644028B2 (en) 2013-02-15 2017-05-09 Perseus Proteomics Inc. Anti-CDH3 humanized antibody, drug conjugate thereof, and use thereof
WO2018034354A1 (ja) * 2016-08-19 2018-02-22 富士フイルムＲｉファーマ株式会社 緩衝剤を含む組成物
CN109641069A (zh) * 2016-08-19 2019-04-16 富士胶片富山化学株式会社 含有缓冲剂的组合物
JPWO2018034354A1 (ja) * 2016-08-19 2019-06-20 富士フイルム富山化学株式会社 緩衝剤を含む組成物
JP7104274B2 (ja) 2016-08-19 2022-07-21 Ｐｄｒファーマ株式会社 緩衝剤を含む組成物
US11951168B2 (en) 2016-08-19 2024-04-09 Perseus Proteomics Inc. Composition containing buffer
WO2025089383A1 (ja) * 2023-10-26 2025-05-01 株式会社ペルセウスプロテオミクス ２２５Ａｃ標識抗ＣＤＨ３抗体
WO2025109003A1 (en) 2023-11-21 2025-05-30 3B Pharmaceuticals Gmbh P-cadherin ligands

Also Published As

Publication number Publication date
JP5848737B2 (ja) 2016-01-27
EP2535358B1 (en) 2017-12-20
CA2789310A1 (en) 2011-08-18
CN102892787B (zh) 2015-04-29
BR112012020116B1 (pt) 2021-12-14
ES2656168T3 (es) 2018-02-23
LT2535358T (lt) 2018-03-26
NO2535358T3 (enExample) 2018-05-19
HUE037817T2 (hu) 2018-09-28
CA2789310C (en) 2018-01-09
US20140328754A1 (en) 2014-11-06
EP2535358A1 (en) 2012-12-19
PL2535358T3 (pl) 2018-05-30
US8815211B2 (en) 2014-08-26
KR20120115995A (ko) 2012-10-19
US20130071324A1 (en) 2013-03-21
RS57008B1 (sr) 2018-05-31
EP2535358A4 (en) 2013-07-10
CY1120012T1 (el) 2018-12-12
RU2012138459A (ru) 2014-03-20
CN102892787A (zh) 2013-01-23
JPWO2011099524A1 (ja) 2013-06-13
EP2535358A9 (en) 2014-03-26
AU2011215267B2 (en) 2016-07-07
PT2535358T (pt) 2018-02-23
BR112012020116A2 (pt) 2020-08-18
KR101900110B1 (ko) 2018-09-18
RU2577125C2 (ru) 2016-03-10
DK2535358T3 (en) 2018-02-05
AU2011215267A1 (en) 2012-09-06
JP2014012731A (ja) 2014-01-23
HRP20180293T1 (hr) 2018-03-23
SI2535358T1 (en) 2018-03-30
JP5380553B2 (ja) 2014-01-08
SG183272A1 (en) 2012-09-27
BR112012020116B8 (pt) 2023-01-10

Similar Documents

Publication Publication Date Title
JP5848737B2 (ja) 放射性金属標識抗カドヘリン抗体
JP6006640B2 (ja) 高い内在化能力を有する抗ｃｄｈ３抗体
EP2573120B1 (en) Anti-human trop-2 antibody having anti-tumor activity in vivo
US9127061B2 (en) Anti-human P-cadherin (CDH3) recombinant antibody
EP2848686B1 (en) Conjugate of anti-cdh3 (p-cadherin) antibody and drug
WO2012057315A1 (ja) 高い親和性を有する抗cdh3抗体
WO2014126198A1 (ja) 抗ｃｄｈ３ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用
EP4032908A1 (en) Anti-pd-l1 antibody and pharmaceutical use thereof
HK1175477A (en) Radioactive metal-labeled anti-cadherin antibody
HK1175477B (en) Radioactive metal-labeled anti-cadherin antibody
HK40034094A (en) Anti-cdh3 antibody having high internalization capacity
HK1261879B (en) Anti-cdh3 antibody having high internalization capacity
HK1261879A1 (en) Anti-cdh3 antibody having high internalization capacity
HK1188222A (en) Anti-cdh3 antibody having high internalization capacity

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180009219.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11742267

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011553868

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2011742267

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2789310

Country of ref document: CA

Ref document number: 20127020785

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 6930/DELNP/2012

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13578462

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011215267

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2011215267

Country of ref document: AU

Date of ref document: 20110209

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012138459

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012020116

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012020116

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120810